You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia
|
|---|---|
| Published in |
Leukemia & Lymphoma, November 2017
|
| DOI | 10.1080/10428194.2017.1397661 |
| Pubmed ID | |
| Authors |
Josep-Maria Ribera, Mireia Morgades, Pau Montesinos, Rodrigo Martino, Pere Barba, Beatriz Soria, Arancha Bermúdez, María-José Moreno, José González-Campos, Susana Vives, Cristina Gil, Eugenia Abella, Ramon Guàrdia, Daniel Martínez-Carballeira, Pilar Martínez-Sánchez, María-Luz Amigo, Santiago Mercadal, Alfons Serrano, Aurelio López-Martínez, Ferran Vall-Llovera, María-José Sánchez-Sánchez, María-Jesús Peñarrubia, María Calbacho, Jose-Angel Méndez, Juan Bergua, Antonia Cladera, Mar Tormo, Daniel García-Belmonte, Evarist Feliu, Juana Ciudad, Alberto Orfao, Spanish Society of Hematology on behalf of the PETHEMA Group |
| Abstract |
Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3-4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 9 | 60% |
| United States | 1 | 7% |
| Unknown | 5 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 67% |
| Practitioners (doctors, other healthcare professionals) | 3 | 20% |
| Scientists | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 15% |
| Student > Ph. D. Student | 6 | 11% |
| Student > Bachelor | 5 | 9% |
| Student > Master | 5 | 9% |
| Researcher | 5 | 9% |
| Other | 10 | 18% |
| Unknown | 16 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 27% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Business, Management and Accounting | 2 | 4% |
| Psychology | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 22 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2018.
All research outputs
#4,221,772
of 23,008,860 outputs
Outputs from Leukemia & Lymphoma
#323
of 4,017 outputs
Outputs of similar age
#90,212
of 437,841 outputs
Outputs of similar age from Leukemia & Lymphoma
#10
of 49 outputs
Altmetric has tracked 23,008,860 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,017 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,841 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.